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INTRODUCTION
Flumazenil, an imidazobenzodiazepine, is the first benzo-
diazepine antagonist and is being used to reverse the adverse
pharmacological effects of benzodiazepine. Other potential
indications include hepatic encephalopathy, and other forms
of coma (1). Flumazenil is a relative safe drug, with rare central
nevous system (CNS) side effects, such as seizure, agitation
and anxiety (2-4).
We report a case of ballistic movements that developed
following the administration of flumazenil. 
CASE REPORT
A 58-yr-old woman was found suffering from drowsiness
and was transported to the emergency room. The patient had
been treated with hemodialysis for chronic renal failure for
the previous 10 yr. Her medication included 100 mg aspirin,
10 mg baclofen, and 5 mg amitriptyline hydrochloride. She
had never been on any neuroleptic or dopaminergic drugs
and there was no past history of neurological disease.  
On admission, she was confused, disoriented and drowsy,
with a blood pressure of 120/90 mmHg, a regular heart beat
of 96 beats/min, and a temperature of 36.8℃. Physical exami-
nation did not demonstrate any pathologic findings. Neuro-
logic findings were as follows: slightly dilated pupils, respon-
sive to light, normal corneal, oculocephalic, and gag reflexes,
decreased deep tendon reflexes, and symmetrical muscle flac-
cidity.
Laboratory tests included a sodium level of 141 mEq/L,
potassium 4.1 mEq/L, creatinine 3.1 mg/dL, blood urea
nitrogen 37.3 mg/dL, glucose 131 mg/dL, HbA1C 6.2%,
white blood cell count 8,700/ L, hemoglobin 13.1 g/dL,
platelet count 313,000/ L, and normal thyroid function. A
brain MRI obtained on admission did not demonstrate any
abnormality.
To diagnose and treat unexplained decreased mentality,
intravenous flumazenil was administered in increments of
0.25 mg/min. The patient regained full consciousness fol-
lowing a total dose of 1.0 mg of flumazenil. One hour later,
the patient developed ballistic movements of the proximal
portion of the upper and lower limbs. The movements could
be described as flexion/extension writhing movements of
her limbs and grimacing of her face. These movements dis-
appeared when she was asleep. On neurological examination,
the patient was found to be alert and attentive. The cranial
nerves were normal. There was no evidence of pyramidal dis-
turbance. Power was full in all muscle groups. There was no
abnormal subjective or objective sensory disturbance. Deep
tendon reflexes were symmetric and normoactive and both
plantar were flexor. All drugs were discontinued and her
symptoms resolved within 3 days.
DISCUSSION
Experimental chorea models can be produced by injecting
a  -aminobutylic acid (GABA) antagonist into the external
pallidum (GPe) or subthalamic nucleus (STN) (5, 6). The
interruption of GABAergic transmission from the striatum
to the GPe would lead to an abnormally increased GPe neu-
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Flumazenil-induced Ballism
Flumazenil, an imidazobenzodiazepine, is the first benzodiazepine antagonist and
is being used to reverse the adverse pharmacological effects of benzodiazepine.
There have been a few reports on the central nevous system side effects with
its use. We report a patient with generalized ballism following administration of
flumazenil. The mechanism through which flumazenil induced this symptom is
unknown. It is conceivable that flumazenil may antagonize the GABA-benzodi-
azepine receptor complex and induce dopamine hypersensitivity, thus induce
dyskinesic symptoms.
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ronal activity, which exerts an inhibitory action upon the STN
(7). Increased STN inhibition would result in the loss of its
control on the internal pallidum (GPi). Besides excitatory STN
inputs (8), the GPi neurons also receive inhibitory afferent
inputs directly from the striatum. The imbalance between
the indirect excitatory and direct inhibitory pathways would
ultimately lead to a disinhibition of the motor thalamus. 
Benzodiazepines exert their main action on the central
nevous system primarily by an enhancement of GABAergic
synaptic transmission (9). These effects are mediated by the
interaction of benzodiazepines with specific neuronal mem-
brane proteins, the benzodiazepine receptors, which are
localized, at least in part, in the GABAergic synapses (10).
These GABAmimetic activities have been used effectively
in the treatment of acquired and non-acquired chorea/bal-
lism (11). 
Flumazenil selectively antagonizes the central actions of
benzodiazepines by competitive interaction at the GABA-
benzodiazepine receptor level. In addition, animal studies
have shown that flumazenil can influence dopamine meta-
bolism in the central nervous system. Flumazenil has been
shown to increase the extracellular dopamine of mesolimbic
dopaminergic neuron following repeated administration of
benzodiazepine receptor partial agonists. Therefore, the ad-
ministration of flumazenil may increase dopamine availability,
in turn increasing dopamine receptor sensitivity (13). 
The occurrence of a ballistic movement in our patient fol-
lowing the administration of flumazenil suggests a possible
relationship between flumazenil and ballism, although the
mechanism is not known and the short half-life of flumaze-
nil effect makes flumazenil-related ballism unlikely. Since
the drug was completely eliminated from the body within
48-72 hr following infusion of flumazenil (1), the effect of
flumazenil did correlate with the duration of the patient’s
symptom. A potential explanation is that flumazenil may
antagonize the GABA-benzodiazepine receptor complex
and/or induce dopamine hypersensitivity and, therefore, cause
dyskinesic symptoms. 
It is of course possible that this symptom may be unrelat-
ed to flumazenil. In addition, as previously reported (14),
other drug such as baclofen cannot be ruled out in relation
to this condition. However, the long-term use of this drug
without specific side-effects makes baclofen-induced dyski-
nesia unlikely in our case. 
In summary, the temporal relationship to the administra-
tion of flumazenil and the absence of a clear etiology on the
MRI support the association between flumazenil and ballism,
despite the fact that a cause-and-effect relationship cannot
be clearly inferred.
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